Study: NCT02099110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo to Ertugliflozin 5 mg
Description: Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo to Ertugliflozin 10 mg
Description: Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo to Ertugliflozin 10 mg
Description: Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo to Ertugliflozin 10 mg
Description: Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo to sitagliptin 100 mg
Description: Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo to sitagliptin 100 mg
Description: Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg
Description: Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg
Description: Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin >= 1500 mg/day
Description: Metformin \>= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin >= 1500 mg/day
Description: Metformin \>= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin >= 1500 mg/day
Description: Metformin \>= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin >= 1500 mg/day
Description: Metformin \>= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin >= 1500 mg/day
Description: Metformin \>= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Glargine Rescue Medication
Description: Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Glargine Rescue Medication
Description: Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Glargine Rescue Medication
Description: Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Glargine Rescue Medication
Description: Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine Rescue Medication
Description: Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Rescue Medication
Description: Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Rescue Medication
Description: Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Rescue Medication
Description: Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Rescue Medication
Description: Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride Rescue Medication
Description: Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion